FSH, Training, and Exercise: What Your Levels Are Telling You

What FSH Actually Measures

FSH is a glycoprotein hormone secreted by the anterior pituitary in response to gonadotropin-releasing hormone (GnRH) pulses from the hypothalamus. In women, FSH drives follicular growth each cycle. In men, it supports spermatogenesis in the Sertoli cells of the testes. The level you see on a blood panel reflects the net output of a hypothalamic-pituitary-gonadal (HPG) axis that is sensitive to metabolic signals, including the ones generated by hard training.

The HPG Axis and Why It Responds to Exercise

The hypothalamus does not operate in isolation. It monitors circulating glucose, leptin, insulin-like growth factor-1 (IGF-1), and kisspeptin. When energy balance turns negative, kisspeptin neurons in the arcuate nucleus reduce GnRH pulse frequency. Lower GnRH pulse frequency reduces FSH and LH secretion from the pituitary. This cascade is the mechanistic bridge between intense exercise, low caloric intake, and disrupted reproductive function.

A 2017 review in Endocrine Reviews described kisspeptin as "a critical gatekeeper of reproductive function, integrating metabolic and environmental signals" to modulate GnRH output [1]. That gatekeeper function is exactly why a marathon runner's FSH can look more like a perimenopausal woman's FSH, or the reverse depending on context.

FSH Reference Ranges by Phase and Sex

Reference intervals vary by laboratory assay, but the widely cited Endocrine Society ranges are a reasonable baseline [2]:

| Population | FSH Range (mIU/mL) | |---|---| | Women, follicular phase (day 2 to 4) | 3.5 to 12.5 | | Women, mid-cycle surge | 4.7 to 21.5 | | Women, luteal phase | 1.7 to 7.7 | | Women, postmenopause | 25.8 to 134.8 | | Men, adult | 1.5 to 12.4 | | Prepubertal children | <2.0 |

Always confirm which cycle day was used for the draw before interpreting a result. A day-21 FSH of 6 mIU/mL is normal; a day-3 FSH of 6 mIU/mL is also normal. A day-3 FSH of 18 mIU/mL signals diminished ovarian reserve.

How Acute Exercise Changes FSH

A single bout of moderate-to-vigorous exercise produces a short-lived FSH change. Several controlled studies show a transient 10 to 20% rise in FSH during prolonged aerobic exercise, followed by return to baseline within 1 to 2 hours post-exercise [3]. The rise is thought to reflect a brief GnRH pulse triggered by the sympatho-adrenal stress response rather than a change in ovarian or testicular feedback.

What This Means for Lab Timing

This transient shift is clinically relevant when scheduling blood draws. Collecting FSH within two hours of a hard workout may inflate the result by 10 to 20%. For the most interpretable FSH reading, the HealthRX medical team recommends drawing blood in a rested, fasted state, at least 12 hours after the last bout of vigorous exercise, and on cycle days 2 to 4 for premenopausal women.

Acute Exercise in Men

The same transient FSH rise has been documented in male athletes after high-intensity interval training (HIIT) sessions exceeding 60 minutes [4]. The rise typically resolves within 90 minutes. Resting FSH values in well-trained men are not consistently different from sedentary controls at matched body composition, which separates the acute effect from any chronic adaptation.

Chronic Overtraining and FSH Suppression

Sustained high training volume combined with inadequate energy intake produces a different picture entirely. This is the domain of Relative Energy Deficiency in Sport (RED-S), formerly called the Female Athlete Triad.

RED-S and the Female Athlete

The International Olympic Committee's 2023 consensus statement on RED-S identifies low energy availability as the primary driver of reproductive suppression in female athletes [5]. When energy availability drops below roughly 30 kcal per kilogram of fat-free mass per day, GnRH pulsatility deteriorates, and both LH and FSH fall. The result is functional hypothalamic amenorrhea (FHA).

In FHA, FSH typically drops below 5 mIU/mL and may fall below 3 mIU/mL in severe cases. Estradiol falls proportionally. Bone density suffers within 6 to 12 months of untreated FHA, according to a longitudinal study of 65 female collegiate athletes followed for one academic year [6]. Restoring energy availability, rather than reducing training, is the first-line intervention recommended by both the IOC and the American College of Sports Medicine.

FSH Suppression in Male Athletes

Overtrained male athletes show a parallel pattern. A 2019 prospective study of 14 competitive male cyclists completing a 3-week intensification block found mean FSH fell 22% from baseline (P<0.05) by week 3, recovering to baseline within 2 weeks of reduced load [7]. Total testosterone declined concurrently. The study authors noted that FSH suppression tracked closely with subjective overtraining scores on the Hooper Index, suggesting FSH may serve as a quantitative overtraining biomarker in men as well.

How to Distinguish Overtraining Suppression from Pituitary Pathology

Functional suppression from overtraining resolves with rest and refeeding, typically within 4 to 8 weeks. Pituitary pathology (prolactinoma, Sheehan syndrome, hemochromatosis) does not. A clinically useful next step when FSH stays low despite 6 weeks of reduced training is to check prolactin, IGF-1, and a morning cortisol alongside a repeat FSH. A serum prolactin above 25 ng/mL in women or above 15 ng/mL in men warrants pituitary MRI before attributing low FSH to training alone.

FSH, Body Composition, and Weight Loss

Fat mass and FSH interact in a dose-dependent way. Adipose tissue aromatizes androgens to estrogens, and higher circulating estrogens suppress FSH through negative feedback on the pituitary. This means women with high body fat often show lower FSH values than expected for their age and menopausal status.

GLP-1 Agonists, Caloric Restriction, and FSH

Rapid weight loss from GLP-1 receptor agonists (semaglutide, tirzepatide) or aggressive caloric restriction can temporarily unmask a higher FSH as estrogen production from adipose tissue falls. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% on placebo [8]. While STEP-1 did not specifically track FSH, case series from HealthRX's clinical practice show that women near perimenopause who lose more than 10% of body weight over 6 months via GLP-1 therapy frequently see FSH rise by 5 to 15 mIU/mL, sometimes crossing the diagnostic threshold for menopause for the first time.

This FSH unmasking effect has practical consequences for HRT prescribing. A woman who starts semaglutide at age 48, loses 18 kg over 9 months, and then shows a day-3 FSH of 28 mIU/mL may be experiencing both true perimenopause and weight-loss-related estrogen withdrawal. Distinguishing the two requires serial FSH draws 4 to 6 weeks apart alongside symptom tracking and estradiol levels.

Resistance Training and Body Composition Improvement

Unlike endurance overtraining, progressive resistance training without caloric restriction does not consistently suppress FSH. A 12-week randomized controlled trial of 44 sedentary postmenopausal women assigned to resistance training 3 times per week showed no significant change in FSH versus control (mean change +1.3 mIU/mL in training group vs. +0.9 mIU/mL in control, P=0.61) [9]. Resistance training improved lean mass, insulin sensitivity, and hip bone mineral density without perturbing the HPG axis. This is a meaningful finding for clinicians recommending exercise in the menopause transition.

FSH as a Perimenopause and Menopause Marker

The North American Menopause Society defines menopause as 12 consecutive months of amenorrhea without another cause, confirmed when FSH exceeds 40 mIU/mL on two measurements at least 4 to 6 weeks apart [10]. This threshold matters for HRT eligibility and for stopping contraception.

When FSH Is Unreliable for Menopause Staging

Four clinical scenarios reduce FSH reliability for menopause staging:

1. Active competitive training at high volumes (functional suppression, as above)
2. Recent GnRH agonist or antagonist therapy (leuprolide, cetrorelix)
3. Recent high-dose progestin use, which can transiently suppress FSH
4. Obesity with high aromatization, which blunts the FSH rise

The Menopause Society guideline states: "FSH measurement in isolation is insufficient to diagnose menopause in women on hormonal contraception or those with significant metabolic conditions affecting estrogen production" [10]. Combining FSH with estradiol (both low confirms ovarian quiescence), Anti-Müllerian hormone (AMH), and clinical history produces a more reliable picture.

AMH as a Complementary Marker for Active Athletes

AMH does not fluctuate with the menstrual cycle and is not suppressed by exercise-related hypothalamic changes the way FSH is. For active women where FSH interpretation is complicated by training status, AMH offers a direct measure of ovarian reserve that is exercise-independent [11]. An AMH below 0.5 ng/mL in a 35-year-old female athlete with an FSH of 4 mIU/mL is more concerning for diminished reserve than the FSH value alone suggests.

Optimal FSH Targets in Different Clinical Contexts

"Optimal" FSH depends on the clinical question. There is no single target number.

Fertility and Ovarian Reserve

For women pursuing natural conception or assisted reproduction, a day-3 FSH below 10 mIU/mL is generally considered favorable. The Society for Assisted Reproductive Technology (SART) uses FSH above 10 mIU/mL combined with antral follicle count below 5 as markers of reduced response to ovarian stimulation [12]. Above 15 to 20 mIU/mL, response to gonadotropin stimulation falls substantially and live-birth rates per retrieval cycle decline.

Perimenopause Management and HRT

For HRT candidacy, a confirmed FSH above 25 to 40 mIU/mL alongside appropriate symptoms (vasomotor symptoms, sleep disruption, vaginal dryness) supports initiating hormone therapy in women aged 45 and older. There is no FSH target to maintain on HRT. Once therapy is started, FSH is not routinely monitored unless symptoms are inadequately controlled or there is concern about therapy adherence or absorption.

Male Hypogonadism Evaluation

In men, a low-normal or low FSH combined with low testosterone points to secondary (central) hypogonadism, where the pituitary is not driving the testes adequately. This pattern can result from overtraining, exogenous anabolic steroid use, or pituitary disease. A high FSH combined with low testosterone indicates primary hypogonadism, where the testes themselves are failing. This distinction changes treatment completely: secondary hypogonadism in a man who wants fertility is often treated with clomiphene citrate or FSH injections rather than exogenous testosterone, which would suppress spermatogenesis further.

Interpreting FSH Alongside Other Lab Markers

FSH never exists in isolation on a lab panel. The most informative pattern recognition involves pairing FSH with related markers.

FSH and LH Ratio

The FSH-to-LH ratio at baseline (cycle day 2 to 4) carries information. An FSH:LH ratio above 2 on day 3 has been associated with diminished ovarian reserve in several fertility studies, independent of the absolute FSH value [13]. In polycystic ovarian syndrome (PCOS), the ratio is typically inverted, with LH significantly exceeding FSH, though FSH itself may be in the low-normal range.

FSH and Estradiol

A day-3 estradiol above 60 to 80 pg/mL alongside an FSH below 10 mIU/mL can mask ovarian aging. The elevated estradiol provides negative feedback that artificially suppresses FSH, producing a falsely reassuring result. For this reason, estradiol is drawn at the same time as FSH during fertility evaluations. An estradiol above 80 pg/mL on day 3 should prompt caution even when FSH looks normal.

FSH and AMH Together in the Athlete

The table below summarizes how to interpret combined FSH and AMH findings in a physically active woman aged 30 to 45:

| FSH (day 3) | AMH | Most Likely Interpretation | |---|---|---| | <10 mIU/mL | >1.0 ng/mL | Normal reserve, exercise unlikely impairing HPG | | <5 mIU/mL | <0.5 ng/mL | Diminished reserve despite normal-appearing FSH; recheck with reduced training | | <3 mIU/mL | <0.3 ng/mL | Suspect RED-S or FHA; reduce load, improve energy availability | | >15 mIU/mL | <0.5 ng/mL | Diminished reserve; consider referral to reproductive endocrinology | | >15 mIU/mL | >1.0 ng/mL | Discordant; check for recent acute exercise before draw, repeat in 4 to 6 weeks |

Practical Lab Ordering Protocol for Active Patients

Getting an accurate FSH on an athlete or highly active individual requires attention to four variables.

Timing Rules for the Best Draw

Draw FSH on cycle days 2 to 4 for premenopausal women. Avoid drawing within 48 hours of a high-intensity training block. If the patient is in a heavy training phase, a 5 to 7 day taper before the draw will reduce the chance of transient suppression artifacts. Document recent training volume and caloric intake in the chart when ordering, so the reviewing clinician has context.

Serial Measurements Over Single Snapshots

A single FSH value is almost never sufficient for clinical decisions in active patients. Two draws at least 4 to 6 weeks apart, matched to the same cycle day where possible, provide a trajectory rather than a snapshot. In men, two draws at least 2 weeks apart are reasonable given the lack of a cycle.

What to Add to the Panel

For the most complete picture in an active patient concerned about fertility, perimenopause, or training-induced HPG suppression, order FSH alongside LH, estradiol (in women), total and free testosterone (in men), AMH (in women under 45), prolactin, and SHBG. Adding a morning cortisol and IGF-1 helps rule out adrenal fatigue and growth hormone axis disruption when overtraining is suspected.

The Endocrine Society clinical practice guideline on female hypogonadism states: "Measurement of FSH alone is inadequate to characterize the hypothalamic-pituitary-ovarian axis; concurrent measurement of LH and estradiol is necessary for accurate classification of hypogonadotropic versus hypergonadotropic states" [2].